# OnCo record da-remternetug (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/da-remternetug/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "da-remternetug" ;
  schema:name "Remternetug"@en ;
  schema:description "Remternetug is an investigational amyloid antibody. It is not approved. Trial eligibility is not a treatment recommendation."@en ;
  schema:url <https://onco.cc/drugs/da-remternetug/> ;
  schema:dateModified "2026-09-21"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/search?intr=remternetug> ;
  onco:status "phase-3" ;
  onco:tag "dementia-atlas" ;
  onco:modality "mAb" ;
  onco:cancers <https://onco.cc/diagnoses/alzheimers-disease/> ;
  onco:targets <https://onco.cc/targets/da-target-amyloid-beta/> ;
  onco:companies <https://onco.cc/companies/da-lilly/> .